These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 23769580

  • 1. Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: a meta-analysis of randomized controlled trials.
    Li XM, Wang FC, Yang F, Jin YH.
    Chin Med J (Engl); 2013; 126(11):2179-85. PubMed ID: 23769580
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
    Mathers Dunbar L, Hassman J, Tellier G.
    Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
    [Abstract] [Full Text] [Related]

  • 3. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
    Niederman MS, Chang JR, Stewart J, Asche CV, Lavin B, Nusrat R, Sullivan SD.
    Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
    [Abstract] [Full Text] [Related]

  • 4. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B.
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [Abstract] [Full Text] [Related]

  • 5. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
    Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD.
    Curr Med Res Opin; 2004 May; 20(5):739-47. PubMed ID: 15140341
    [Abstract] [Full Text] [Related]

  • 6. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
    Niederman MS, Chang JR, Stewart J, Nusrat R, Nieman RB.
    Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
    [Abstract] [Full Text] [Related]

  • 7. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J.
    Int J Clin Pract; 2003 May; 57(6):519-29. PubMed ID: 12918892
    [Abstract] [Full Text] [Related]

  • 8. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R.
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [Abstract] [Full Text] [Related]

  • 9. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
    Fogarty CM, Buchanan P, Aubier M, Baz M, van Rensburg D, Rangaraju M, Nusrat R.
    Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
    [Abstract] [Full Text] [Related]

  • 10. Telithromycin: the first ketolide antimicrobial.
    Nguyen M, Chung EP.
    Clin Ther; 2005 Aug; 27(8):1144-63. PubMed ID: 16199242
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study.
    Quinn J, Ruoff GE, Ziter PS.
    Clin Ther; 2003 Feb; 25(2):422-43. PubMed ID: 12749505
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacoeconomic analysis of community-acquired pneumonia treatment with telithromycin or clarithromycin].
    Rubio-Terrés C, Cots JM, Domínguez-Gil A, Herreras A, Sánchez Gascón F, Chang J, Trilla A.
    Rev Esp Quimioter; 2003 Sep; 16(3):295-303. PubMed ID: 14702121
    [Abstract] [Full Text] [Related]

  • 13. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline.
    Zuckerman JM, Qamar F, Bono BR.
    Infect Dis Clin North Am; 2009 Dec; 23(4):997-1026, ix-x. PubMed ID: 19909895
    [Abstract] [Full Text] [Related]

  • 14. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M.
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [Abstract] [Full Text] [Related]

  • 15. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
    Carbon C.
    Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
    [Abstract] [Full Text] [Related]

  • 16. Telithromycin: the first of the ketolides.
    Shain CS, Amsden GW.
    Ann Pharmacother; 2002 Mar; 36(3):452-64. PubMed ID: 11895060
    [Abstract] [Full Text] [Related]

  • 17. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D.
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [Abstract] [Full Text] [Related]

  • 18. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM, Visser M, Mac Dougall N, Coco B, Tomé G, Gliosca L, Grupo Colaborativo de Telitromicina del Cono Sur.
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [Abstract] [Full Text] [Related]

  • 19. Telithromycin.
    Spiers KM, Zervos MJ.
    Expert Rev Anti Infect Ther; 2004 Oct; 2(5):685-93. PubMed ID: 15482232
    [Abstract] [Full Text] [Related]

  • 20. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.
    Carbon C, van Rensburg D, Hagberg L, Fogarty C, Tellier G, Rangaraju M, Nusrat R.
    Respir Med; 2006 Apr; 100(4):577-85. PubMed ID: 16376537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.